These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 27230467)

  • 1. Renal and Bone Toxicity with the Use of Tenofovir: Understanding at the End.
    Casado JL
    AIDS Rev; 2016; 18(2):59-68. PubMed ID: 27230467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tenofovir-Associated Kidney Dysfunction and Bone Fracture: A Case Report and Literature Review.
    Athish KK; Nayak Rao S; Marimuthu VH; Krishna V; Arun A
    Cureus; 2024 Jun; 16(6):e61562. PubMed ID: 38962632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenofovir induced Fanconi syndrome in a middle age African female from Kenya, East Africa: Case report and brief literature review.
    Odhiambo F; Nareeba S; Mwangeka G; Njambi A; Nyakebati V
    Clin Case Rep; 2024 Jun; 12(6):e8889. PubMed ID: 38799537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of bone diseases in tenofovir-treated HIV patients.
    Gervasoni C; Minisci D; Meraviglia P; Baldelli S; Clementi E; Rizzardini G; Cattaneo D
    AIDS; 2016 Jun; 30(10):1686-7. PubMed ID: 27243779
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmaceutical Equivalence of Distributed Generic Antiretroviral (ARV) in Asian Settings: The Cross-Sectional Surveillance Study - PEDA Study.
    Sapsirisavat V; Vongsutilers V; Thammajaruk N; Pussadee K; Riyaten P; Kerr S; Avihingsanon A; Phanuphak P; Ruxrungtham K;
    PLoS One; 2016; 11(6):e0157039. PubMed ID: 27322409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.
    Gianotti N; Galli L; Poli A; Salpietro S; Nozza S; Carbone A; Merli M; Ripa M; Lazzarin A; Castagna A
    Medicine (Baltimore); 2016 May; 95(22):e3780. PubMed ID: 27258510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.
    La Rosa AM; Harrison LJ; Taiwo B; Wallis CL; Zheng L; Kim P; Kumarasamy N; Hosseinipour MC; Jarocki B; Mellors JW; Collier AC;
    Lancet HIV; 2016 Jun; 3(6):e247-58. PubMed ID: 27240787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment failure and drug resistance in HIV-positive patients on tenofovir-based first-line antiretroviral therapy in western Kenya.
    Brooks K; Diero L; DeLong A; Balamane M; Reitsma M; Kemboi E; Orido M; Emonyi W; Coetzer M; Hogan J; Kantor R
    J Int AIDS Soc; 2016; 19(1):20798. PubMed ID: 27231099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection.
    Bedimo R; Rosenblatt L; Myers J
    HIV Clin Trials; 2016 Nov; 17(6):246-266. PubMed ID: 27809711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: A case report.
    Novick TK; Choi MJ; Rosenberg AZ; McMahon BA; Fine D; Atta MG
    Medicine (Baltimore); 2017 Sep; 96(36):e8046. PubMed ID: 28885375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptomic analyses of RNA-binding proteins reveal eIF3c promotes cell proliferation in hepatocellular carcinoma.
    Li T; Li S; Chen D; Chen B; Yu T; Zhao F; Wang Q; Yao M; Huang S; Chen Z; He X
    Cancer Sci; 2017 May; 108(5):877-885. PubMed ID: 28231410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adding dexmedetomidine to ropivacaine for femoral nerve block inhibits local inflammatory response.
    Li J; Wang H; Dong B; Ma J; Wu X
    Minerva Anestesiol; 2017 Jun; 83(6):590-597. PubMed ID: 28106354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
    Fong TL; Lee BT; Tien A; Chang M; Lim C; Ahn A; Bae HS
    J Viral Hepat; 2019 May; 26(5):561-567. PubMed ID: 30576085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
    DeJesus E; Haas B; Segal-Maurer S; Ramgopal MN; Mills A; Margot N; Liu YP; Makadzange T; McCallister S
    AIDS Res Hum Retroviruses; 2018 Apr; 34(4):337-342. PubMed ID: 29368537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
    Hill A; Hughes SL; Gotham D; Pozniak AL
    J Virus Erad; 2018 Apr; 4(2):72-79. PubMed ID: 29682298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Tenofovir Alafenamide Safer than Tenofovir Disoproxil Fumarate for the Kidneys?
    Aloy B; Tazi I; Bagnis CI; Gauthier M; Janus N; Launay-Vacher V; Deray G; Tourret J
    AIDS Rev; 2016; 18(4):184-192. PubMed ID: 27438578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.
    Tao X; Lu Y; Zhou Y; Zhang L; Chen Y
    Int J Infect Dis; 2020 Apr; 93():108-117. PubMed ID: 31988012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal effects of non-tenofovir antiretroviral therapy in patients living with HIV.
    McLaughlin MM; Guerrero AJ; Merker A
    Drugs Context; 2018; 7():212519. PubMed ID: 29623097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Agarwal K; Brunetto M; Seto WK; Lim YS; Fung S; Marcellin P; Ahn SH; Izumi N; Chuang WL; Bae H; Sharma M; Janssen HLA; Pan CQ; Çelen MK; Furusyo N; Shalimar D; Yoon KT; Trinh H; Flaherty JF; Gaggar A; Lau AH; Cathcart AL; Lin L; Bhardwaj N; Suri V; Mani Subramanian G; Gane EJ; Buti M; Chan HLY; ;
    J Hepatol; 2018 Apr; 68(4):672-681. PubMed ID: 29756595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update: Vitamin D
    Dzavakwa NV; Chisenga M; McHugh G; Filteau S; Gregson CL; Kasonka L; Kranzer K; Mabuda HB; Mujuru H; Redzo N; Rowland-Jones S; Schaible UE; Simms V; Ferrand RA;
    Trials; 2024 Jul; 25(1):499. PubMed ID: 39039558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.